Entrada Therapeutics, Inc. has announced its financial results for the third quarter of 2026, alongside significant updates on its clinical programs. The company reported progress in its efforts to develop treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). This update is crucial as it reflects the company's ongoing commitment to addressing unmet medical needs in the neuromuscular disease space.
Founded in Delaware, Entrada Therapeutics operates in the pharmaceutical preparations sector, specifically focusing on developing innovative therapies for serious diseases. The company trades on the Nasdaq under the ticker symbol TRDA. Recent filings include a 10-Q on the same day as this 8-K, indicating active engagement with investors and stakeholders.
According to the recent filing dated November 5, 2026, Entrada reported its financial results for the quarter ended September 30, 2026. The company highlighted that all participants in the ELEVATE-44-201 Cohort 1 have completed open-label dosing, with data expected by the end of 2026. Additionally, the company is on track to report ELEVATE-44-201 Cohort 2 data in the first quarter of 2027.
"The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs," said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
The filing also noted that Entrada has extended its cash runway into the fourth quarter of 2027, with $193 million in cash, cash equivalents, and marketable securities as of September 30, 2026. This financial stability is essential for the company as it continues to advance its clinical programs.
Entrada's recent updates may impact various stakeholders, including investors, healthcare professionals, and patients affected by neuromuscular diseases. The company's focus on DMD and DM1 positions it competitively within the pharmaceutical preparations industry, especially as it collaborates with Vertex Pharmaceuticals on certain studies.
Looking ahead, Entrada is expected to continue providing updates through additional filings and clinical data releases. The company has set a timeline for further data readouts, which will be critical for assessing the potential of its investigational medicines in treating serious neuromuscular diseases.
Read Next
Ronald N. Tutor sells 150,000 shares of Tutor Perini Corp.
Generation Income Properties reports Q3 2026 results
Greenlane Holdings reports Q3 2026 results amid challenges
Permianville Royalty Trust Reports Q3 Financial Results
Cue Biopharma Reports Q3 Results with Financial Insights
Atlantica Inc Reports Q3 Results, Highlights Financial Updates










